Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immune system modulation via reconstitution with induced pluripotent stem cell-derived hematopoietic and immune cells
- Molecular classification
- Other (See note: not a receptor, enzyme, ion channel, etc.; rather, a cell-based therapeutic platform)
01
Overview
This target refers to the use of hematopoietic and immune cells that have been derived from induced pluripotent stem cells (iPSCs) for therapeutic modulation or reconstitution of the immune system. iPSCs can be generated from patient or donor somatic cells and subsequently differentiated into a range of immune and hematopoietic cell types, including macrophages, dendritic cells, lymphocytes, and progenitor cells[4][5][6]. These iPSC-derived cells can be used to model diseases, test drugs, or develop cell therapies for immunodeficiencies, cancer immunotherapy, autoimmune and inflammatory disorders, and other clinical indications. Applications include the replacement of defective cell types, restoration of immune functions, and modulation of immune responses. Important considerations include differentiation protocol fidelity, immune compatibility, risk of tumorigenicity, and maintenance of physiological functions in vitro and in vivo[4][5][6]. To reiterate, this entry does not correspond to a single, well-defined molecular target but to a therapeutic platform leveraging the power of iPSC-based cell differentiation for immune system manipulation. For structured data purposes, it should not be classified as a canonical molecular target[4][5][6].
- Other names
- iPSC-derived immune cell therapyiPSC-derived hematopoietic cell therapyiPSC-based immune system reconstitutioniPSC-derived immunomodulation
02
Mechanism of action
Cellular replacement: Replacement of missing or defective immune/hematopoietic cells with patient-specific or allogeneic iPSC-derived cells Immune modulation: Shift of immune response profile via introduction of functionally tailored cell populations (e.g., regulatory macrophages, antigen-presenting cells) Antigen presentation: Restoration or enhancement of immune recognition via reconstituted antigen-presenting cells Cytokine modulation: Modulation of cytokine milieu by the introduced cells, affecting immune system tone
03
Biological functions
Immune responseImmune modulationTissue regeneration (potential, depending on cell type)Antigen presentation (for iPSC-derived antigen-presenting cells)Cytokine production/regulation
04
Disease associations
Cancer (immunotherapy, cell therapies)Infection (immune reconstitution following immunodeficiency)Immunodeficiencies (such as congenital immune defects, after bone marrow transplant)Inflammatory and autoimmune diseases (modulation or resetting of immune function)Cardiovascular disease (with respect to tissue repair roles)Other (transplantation, regenerative medicine)
05
Safety considerations
Tumorigenicity: Risk of teratoma or tumor formation from residual undifferentiated iPSCsGraft-versus-host disease (depending on immunogenicity and the allogeneic/autologous nature of the cells)Immunogenicity: Potential rejection or immune response against the introduced cells, especially with incomplete or aberrant differentiationFunctional instability: Immortalization or altered phenotype can affect immunological function of iPSC-derived cellsInfection risk (temporary immunosuppression or incomplete immune function post-transfer)
06
Interacting drugs
Dexamethasone (used for functional testing of iPSC-derived macrophages in vitro)
2 more in the full profile.
07
Biomarkers
Lineage-specific markers (e.g., CD14, CD68 for macrophages; CD34 for hematopoietic progenitors)Cytokine levels (especially IL-6, IL-1β, TNF-α, etc. depending on the target cell type and therapeutic context)Chimerism or engraftment markers (tracking donor-derived cells in recipient)Functionality assays (phagocytosis, antigen-presentation, cytokine secretion, etc.)
Beyond the preview
Go deeper on Immune system modulation via reconstitution with induced pluripotent stem cell-derived hematopoietic and immune cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immune system modulation via reconstitution with induced pluripotent stem cell-derived hematopoietic and immune cells.